Alzheimer?s disease (AD) is a progressive neurodegenerative disease affecting more than 30 million people worldwide. It is the most common cause of dementia, and its pathology includes extensive neuronal loss, accumulation of extracellular amyloid-beta (A?) plaques and intracellular neurofibrillary tangles. A number of large scale meta-analyses of genome wide association studies (GWAS) has analyzed polymorphisms in many human subjects, and identified more than 20 genes associated with AD risk, which can be classified based on their known functions: cholesterol metabolism, inflammation, and endocytosis. Our lab seeks to utilize induced pluripotent stem cells (iPSCs) from patients with familial and sporadic AD to understand the cellular mechanisms underlying AD. My proposed project will investigate the potential convergent mechanisms of APOE and SORL1 function in the brain. Both APOE and SORL1 are AD risk genes, and APOE (?4) is the strongest genetic risk factor for AD. Not only is SORL1 a GWAS hit for late onset AD (LOAD), but recent studies identified SORL1 loss-of-function variants in familial AD patients, suggesting that SORL1 can be a potential causal gene for AD. Here, I will study the function of SORL1 as a receptor for APOE, which can address the potential convergent mechanism between these genes. I hypothesize that SORL1 will function as an APOE receptor in human astrocytes and regulate A? clearance. In support of this, publicly available RNA-seq data show that SORL1 transcript is highly expressed in astrocytes over other brain cell types. In addition, APOE has a known role in A? clearance, and SORL1 is in the APOE receptor gene family. These findings, however, do not directly examine the role of SORL1 in regulating A? uptake in astrocytes. Here, I will utilize iPSC-derived astrocytes with different SORL1 and APOE variants to study the ability of SORL1 to function as an APOE receptor and uptake A?.
In Aim 1, I will generate iPSC-derived astrocytes and determine SORL1 expression, subcellular localization, and ligand binding characteristics. Then, In Aim 2, I will use iPSC-derived astrocytes generated from individuals with 1) different APOE isoforms 2) SORL1 knock out (KO), risk SNPs and missense mutations and 3) other AD risk SNPs. I then will meticulously characterize A? generation, uptake and clearance in these astrocytes. Our preliminary data suggest that SORL1 is highly expressed in human astrocytes, and SORL1 KO in these astrocytes results in elevated extracellular A? levels. Also, I have shown that iPSC-derived astrocytes reduce extracellular A? levels when treated with exogenous A?, opening up the possibility/potential for this assay to examine the A? clearance ability of cells from individuals with various genetic backgrounds. In summary, my proposal will utilize iPSC-derived astrocytes to examine the novel role of SORL1 as an APOE receptor in astrocytes, and investigate a potential convergent mechanism that APOE and SORL1 play in A? clearance.
While numerous genetic studies have identified more than 20 genes linked to increasing the risk of developing Alzheimer?s disease (AD), the mechanistic link between these genes and amyloid-beta (A?) accumulation in the brain is yet unclear. Interestingly, APOE, the strongest genetic risk factor for AD, is a gene involved in generating lipoproteins that can directly interact with A? and regulate clearance of A?, and SORL1, another AD risk gene, belongs to a family of proteins that can mediate this clearance of A?. My work aims to investigate the novel role of SORL1 in human astrocytes by examining its role in mediating A? clearance.
